Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Epileptology

Background:

• Infantile spasms (IS) are a severe epilepsy syndrome in infants.
• Refractory IS poses significant treatment challenges and impacts long-term neurodevelopment.
• Limited effective therapeutic options exist for persistent infantile spasms.

Purpose of the Study:

• To evaluate the safety and efficacy of ganaxolone as an add-on therapy for children with refractory infantile spasms.
• To determine the optimal dose and tolerability of ganaxolone in this pediatric population.
• To assess the impact of ganaxolone on spasm frequency and seizure severity.

Main Methods:

• A multicenter, open-label, dose-escalation trial involving 20 children (7 months to 7 years) with refractory IS.
• Ganaxolone dosage was escalated up to 36 mg/kg/d over 4 weeks, maintained for 8 weeks, then tapered.
• Seizure diaries, clinical monitoring of adverse events, and global evaluations were used to assess outcomes.

Main Results:

• 16 of 20 subjects completed the study; 15 had refractory IS at baseline.
• 33% of subjects achieved ≥50% reduction in spasm frequency; an additional 33% had 25-50% improvement.
• Ganaxolone was generally well-tolerated with mild adverse events attributed to the drug.

Conclusions:

• Ganaxolone is safe and effective as an add-on treatment for pediatric refractory infantile spasms.
• The observed efficacy suggests ganaxolone as a promising therapeutic option.
• Randomized, controlled trials are recommended to further validate these findings.